A Study of Bomedemstat Compared to Best Available Therapy in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea

Recruiting

Trial purpose

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythaemia (ET) who have an inadequate response to or are intolerant of hydroxyurea.

The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).

View full trial information on Clinicaltrials.gov

	national trial reference number	NCT06079879
	Conditions	Essential Thrombocythemia
	Age Range	18+
	Sex	All
	Current trial phase	3
	Trial start and end dates	12-31-2023 08-18-2028

Trial locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

NATIONAL TRIAL REFERENCE NUMBER

NCT06079879

When you talk with your doctor or clinical trial team member, please have the national trial reference number available.